Denser under-the-skin fat in HIV patients on tesamorelin was linked to higher IGF-1 levels, a hormone involved in growth and metabolism, suggesting broader metabolic benefits.

Denser under-the-skin fat in HIV patients on tesamorelin was linked to higher levels of the metabolism-regulating hormone adiponectin, suggesting improved fat function.

For HIV patients with belly fat who responded to tesamorelin, denser subcutaneous fat (on CT scans) was linked to less subcutaneous fat area, showing that fat quality and quantity are related.

In HIV patients with belly fat who responded to tesamorelin, thicker subcutaneous fat (on CT scans) was linked to higher adiponectin levels, which is beneficial for metabolic health.

When HIV patients on tesamorelin had denser belly fat, their bodies also produced more adiponectin, a hormone that helps regulate metabolism, showing a link between fat quality and metabolic health.

HIV patients on tesamorelin with denser under-the-skin fat had lower total cholesterol, a key indicator of heart health, suggesting better fat quality may improve cardiovascular risk factors.